{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:43:59Z","timestamp":1775609039607,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Celiac disease (CeD) has shown an association with autoimmune disorders including vitiligo and alopecia areata (AA). Ritlecitinib, a JAK3 and TEC kinase family inhibitor, has been approved for treatment of patients with AA and is in late-stage development for vitiligo. Ritlecitinib inhibits cytotoxic T cells, NK cells, and B cells which play a role in the pathogenesis of CeD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>We aimed to explore the potential effect of ritlecitinib on CeD serology levels before and after ritlecitinib treatment in research participants of clinical trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The effect of ritlecitinib on CeD serology (tTG-IgA, DGP-IgA\/IgG) levels was retrospectively evaluated in participants from three phase 2 and one phase 3 ritlecitinib clinical trials including participants with active AA, rheumatoid arthritis (RA) and vitiligo, whose serum samples at baseline and post-treatment were available. All statistical comparisons of the changes between initial and follow-up samples used the Wilcoxon matched pairs exact test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 1146 research participants, 21 individuals had a positive tTG-IgA in their baseline samples (positivity rate, 0.018, 95% CI\u2009=\u20090.011\u20130.028). Among these 21 individuals, follow-up samples were available in 15 participants from the ritlecitinib group and in 3 from the placebo group. In follow-up samples, the values of tTG-IgA in the 15 participants treated with ritlecitinib significantly decreased from baseline (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), while in the placebo group the tTGA-IgA levels remained close to the baseline values.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>A decrease in CeD serology levels with ritlecitinib treatment suggests that ritlecitinib may provide beneficial effect in CeD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00403-024-03784-6","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T08:11:15Z","timestamp":1737187875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ritlecitinib, a JAK3 \/TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients"],"prefix":"10.1007","volume":"317","author":[{"given":"Rok Seon","family":"Choung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"issue":"1","key":"3784_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.14309\/ajg.0000000000002075","volume":"118","author":"A Rubio-Tapia","year":"2023","unstructured":"Rubio-Tapia A, Hill ID, Semrad C, Kelly CP, Greer KB, Limketkai BN et al (2023) American College of Gastroenterology guidelines Update: diagnosis and management of Celiac Disease. Am J Gastroenterol 118(1):59\u201376","journal-title":"Am J Gastroenterol"},{"key":"3784_CR2","doi-asserted-by":"crossref","unstructured":"Lebwohl B, Soderling J, Roelstraete B, Lebwohl MG, Green PH, Ludvigsson JF (2021) Risk of skin disorders in patients with Celiac Disease: a Population-based Cohort Study. J Am Acad Dermato l85(6):1456\u20131464","DOI":"10.1016\/j.jaad.2020.10.079"},{"issue":"4","key":"3784_CR3","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1053\/j.gastro.2016.11.043","volume":"152","author":"RS Choung","year":"2017","unstructured":"Choung RS, Larson SA, Khaleghi S, Rubio-Tapia A, Ovsyannikova IG, King KS et al (2017) Prevalence and morbidity of undiagnosed Celiac Disease from a community-based study. Gastroenterology 152(4):830\u2013839e5","journal-title":"Gastroenterology"},{"issue":"8","key":"3784_CR4","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/j.1572-0241.2002.05917.x","volume":"97","author":"AS Abdulkarim","year":"2002","unstructured":"Abdulkarim AS, Burgart LJ, See J, Murray JA (2002) Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol 97(8):2016\u20132021","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"3784_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2021.12.008","volume":"87","author":"E Peeva","year":"2022","unstructured":"Peeva E, Guttman-Yassky E, Banerjee A, Sinclair R, Cox LA, Zhu L et al (2022) Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with Alopecia Areata in a single-blind extension of a phase 2a randomized clinical trial. J Am Acad Dermatol 87(2):390\u2013393","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3784_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","volume":"88","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G et al (2023) Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial. J Am Acad Dermatol 88(2):395\u2013403","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3784_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1525-1470.2011.01388.x","volume":"28","author":"C Rodriguez-Garcia","year":"2011","unstructured":"Rodriguez-Garcia C, Gonzalez-Hernandez S, Perez-Robayna N, Guimera F, Fagundo E, Sanchez R (2011) Repigmentation of vitiligo lesions in a child with celiac disease after a gluten-free diet. Pediatr Dermatol 28(2):209\u2013210","journal-title":"Pediatr Dermatol"},{"key":"3784_CR8","doi-asserted-by":"publisher","first-page":"174434","DOI":"10.1016\/j.ejphar.2021.174434","volume":"909","author":"A Kulkarni","year":"2021","unstructured":"Kulkarni A, Patel S, Khanna D, Parmar MS (2021) Current pharmacological approaches and potential future therapies for celiac disease. Eur J Pharmacol 909:174434","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"3784_CR9","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","volume":"11","author":"JB Telliez","year":"2016","unstructured":"Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L et al (2016) Discovery of a JAK3-Selective inhibitor: functional differentiation of JAK3-Selective inhibition over pan-JAK or JAK1-Selective inhibition. ACS Chem Biol 11(12):3442\u20133451","journal-title":"ACS Chem Biol"},{"issue":"2","key":"3784_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1053\/j.gastro.2017.04.023","volume":"153","author":"J Wolf","year":"2017","unstructured":"Wolf J, Petroff D, Richter T, Auth MKH, Uhlig HH, Laass MW et al (2017) Validation of antibody-based strategies for diagnosis of Pediatric Celiac Disease without Biopsy. Gastroenterology 153(2):410\u20139e17","journal-title":"Gastroenterology"},{"issue":"1","key":"3784_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/MPG.0000000000002497","volume":"70","author":"S Husby","year":"2020","unstructured":"Husby S, Koletzko S, Korponay-Szabo I, Kurppa K, Mearin ML, Ribes-Koninckx C et al (2020) European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. J Pediatr Gastroenterol Nutr 70(1):141\u2013156","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"3784_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/MPG.0b013e31821a23d0","volume":"54","author":"S Husby","year":"2012","unstructured":"Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R et al (2012) European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 54(1):136\u2013160","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"3784_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/00004836-200311000-00007","volume":"37","author":"A Tursi","year":"2003","unstructured":"Tursi A, Brandimarte G, Giorgetti GM (2003) Lack of usefulness of anti-transglutaminase antibodies in assessing histologic recovery after gluten-free diet in celiac disease. J Clin Gastroenterol 37(5):387\u2013391","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"3784_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.dld.2021.06.026","volume":"54","author":"F Sbravati","year":"2022","unstructured":"Sbravati F, Cosentino A, Lenzi J, Fiorentino M, Ambrosi F, Salerno A et al (2022) Antitissue transglutaminase antibodies\u2019 normalization after starting a gluten-free diet in a large population of celiac children-a real-life experience. Dig Liver Dis 54(3):336\u2013342","journal-title":"Dig Liver Dis"},{"issue":"1","key":"3784_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/MPG.0000000000002519","volume":"70","author":"N Sansotta","year":"2020","unstructured":"Sansotta N, Alessio MG, Norsa L, Previtali G, Ferrari A, Guerra G et al (2020) Trend of Antitissue transglutaminase antibody normalization in Children with Celiac Disease started on Gluten-free Diet: a comparative study between chemiluminescence and ELISA serum assays. J Pediatr Gastroenterol Nutr 70(1):37\u201341","journal-title":"J Pediatr Gastroenterol Nutr"}],"updated-by":[{"DOI":"10.1007\/s00403-025-04136-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000}}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03784-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03784-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03784-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:56:33Z","timestamp":1741848993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03784-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3784"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03784-6","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00403-025-04136-8","URL":"https:\/\/doi.org\/10.1007\/s00403-025-04136-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JR, VP, and EP are employees of Pfizer and hold stock and\/or stock options with Pfizer. BK has received honoraria and\/or consultation fees from AbbVie, AltruBio, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol Myers Squibb, Concert Pharmaceuticals, Equillium, Horizon Therapeutics, Eli Lilly, Incyte, Janssen Pharmaceuticals, LEO Pharma, Otsuka\/Visterra, Pfizer, Regeneron, Sanofi Genzyme, TWi Biotechnology, and Viela Bio. He previously served on speaker bureaus for AbbVie, Incyte, Eli Lilly, Pfizer, Regeneron, and Sanofi Genzyme. EG received research grants from Leo Pharma, Pfizer, Amgen, GSK, Incyte, Sanofi, Bristol Meyers Squibb, Aslan, Regeneron, Anaptysbio, Concert, Janssen, Q32Bio, Abbvie, Eli-Lilly, Arcutis, Inmagene Bio.; and consultancy fees from Abbvie, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics Limited, Artax Biopharma Inc., Astria, Bristol Meyers Squibb, Boerhinger-Ingelhiem, Calliditas, Cara Therapeutics, Celldex, Centrexion Therapeutics Corporation, Connect Biopharm, Coty, DBV Technologies, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Inc., Fairmount Funds Management LLC, FL2022-001, Inc., Galderma, Gate Bio, Google Ventures (GV), GSK Immunology, Incyte, Inmagene, Janssen Biotech, Jasper Therapeutics, Kymera Therapeutics, Kyowa Kirin, Leo Pharma, Matchpoint Therapeutics, Merck, Nektar Therapeutics, Novartis Pharmaceuticals, NUMAB Therapeutics AG, Nuvig, OrbiMed Advisors LLC, OTSUKA, Pfizer, Pharmaxis Ltd, Pioneering Medicine VII, Inc., Proteologix US Inc, RAPT, RayThera, Inc, Regeneron Pharmaceuticals, RibonTherapeutics, Inc., Rocatinlimab, Sanofi, SATO, Schr\u00f6dinger, Inc., Sitryx, Sun Pharma Advanced Research Company (SPARC), Takeda, Teva Branded Pharmaceutical Products R&D, Inc, UCB, Ventyx Biosyences. JAM has received research grants from Nexpep\/ImmusanT, National Institutes of Health, Immunogenix, Takeda Pharmaceutical, Allakos, ProventionBio, Oberkotter Foundation, and 9\u00a0m, Inc.; contract (to institution) from Kanyos Bio (a wholly owned subsidiary of Anokion); and consultancy fees from Johnson and Johnson, Bristol Myers Squibb, Intrexon Corporation, Dren Bio, Neoleukin, Reistone pharma, Immunic Therapeutics, Senda Biosciences, Brightseed Bio, Chugai Pharma, Alimentiv, Equillium, Ukko, Vial Health Technologies and has received royalties from Torax Medical and Evelo. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}